Horizon Kinetics - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 195 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.

Quarter-by-quarter ownership
Horizon Kinetics ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2018$441,000
+20.5%
24,252
+11.9%
0.01%
+22.2%
Q2 2018$366,000
-3.2%
21,680
+12.5%
0.01%
-18.2%
Q1 2018$378,000
-2.8%
19,272
+0.3%
0.01%0.0%
Q4 2017$389,000
-5.1%
19,208
-18.6%
0.01%
-8.3%
Q3 2017$410,000
+4.3%
23,607
-22.9%
0.01%
-7.7%
Q2 2017$393,000
-1.0%
30,629
+0.0%
0.01%0.0%
Q1 2017$397,000
-2.5%
30,628
-25.6%
0.01%0.0%
Q4 2016$407,000
+2.3%
41,166
+24.9%
0.01%
+18.2%
Q3 2016$398,000
-8.3%
32,970
-34.4%
0.01%0.0%
Q2 2016$434,000
-18.3%
50,240
-10.4%
0.01%
-15.4%
Q1 2016$531,000
-12.7%
56,100
+59.8%
0.01%0.0%
Q4 2015$608,000
+12.0%
35,108
-13.2%
0.01%
+30.0%
Q3 2015$543,000
-42.8%
40,441
-3.9%
0.01%
-28.6%
Q2 2015$950,000
+8.3%
42,087
-31.4%
0.01%
+16.7%
Q1 2015$877,000
-0.2%
61,389
-32.6%
0.01%0.0%
Q4 2014$879,000
+14.6%
91,079
+8.1%
0.01%
+20.0%
Q3 2014$767,000
+0.7%
84,283
+9.2%
0.01%0.0%
Q2 2014$762,000
-4.3%
77,159
+23.2%
0.01%0.0%
Q1 2014$796,000
+49.3%
62,650
+76.3%
0.01%
+42.9%
Q4 2013$533,000
+39.9%
35,532
+2.8%
0.01%
+40.0%
Q3 2013$381,00034,5550.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2018
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders